RxDoctor Payments Data

Teresa Gilliland

Family · Salisbury, MDNPI 1255799540

Payments from drug & device makers

$4,987in general payments, 2019–2025

Across 203 payments — averaging $24.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • GSK$563
  • Novartis$530
  • Sanofi$392
  • CSL Behring$333
  • Amgen$227
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$4,86798%
  • Education$1202%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,987 in reported general payments places this provider in the 90th percentile of 2,843 family providers in Maryland.

See all family providers in Maryland

Medicare billing

Part B allowed, 2024
$15,639
Medicare patients
83
Services billed
777

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter17$11,734
Epinephrine11$2,665
Fluticasone Propionate107$1,838
Wixela InhubFluticasone Propion/Salmeterol11$1,560
Albuterol Sulfate HfaAlbuterol Sulfate37$1,046
Ipratropium Bromide27$885
Levocetirizine Dihydrochloride16$713
Famotidine22$249
Montelukast Sodium21$201
Pantoprazole Sodium12$89
Prednisone21$25

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$563$11,73417 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,843 family providers in Maryland.

Other family in Salisbury

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →